Companies: 10,795·Total market cap: $144.5T
AnaptysBio, Inc.

AnaptysBio, Inc.

ANABNASDAQHealthcare● Active
$51.20
+$0.83(+1.64%)
Market Cap$2.2B
P/E Ratio
52W High$72.36
52W Low$11.404

AnaptysBio, Inc. (ANAB) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

anab · stock forecast · 22 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 22 Wall Street analysts in the past 3 months

SellBuy

Buy

22 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
16
Hold
6
Sell
0
Strong Sell
0
Total: 22 · Buy rate: 72.7%

12-Month Price Target

High

$140

Consensus

$83.14

+63.1% upside

Low

$50.00

Median: $76 · Last Close: $50.98

The AnaptysBio, Inc. (ANAB) analyst consensus is Buy, based on ratings from 22 Wall Street analysts over the past 3 months. The average 12-month ANAB price target is $83.14, representing +63.1% upside from the current price of $50.98.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $83 (63.1%)

Consensus Target

$83.14

63.1% upside

High Target

$140

174.6%

Low Target

$50

-1.9%

Current Price

$50.98

as of today

Based on analyst price targets, the ANAB stock price prediction for the next 12 months ranges from $50 to $140. The consensus ANAB price forecast of $83.14 implies 63.1% upside from the current price of $50.98.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$48.435.00%

1-day model range: $48.17–$48.7. Peak: $48.7 (-5.00%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$92+80.0%
2028$136+166.4%
2029$175+243.1%
2030$205+302.4%
2031+344.1%
Confidence:MediumCapped at 80% annual limit

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

36%0%64%
5Buy
0Neutral
9Sell
RSI (14)20.6Oversold
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · ANAB · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$51.10SELL
MA 10$53.68SELL
MA 20$57.85SELL
MA 50$54.58SELL
MA 100$45.63BUY
MA 200$34.36BUY
Current $ANAB · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$51.65SELL
EMA 10$53.55SELL
EMA 20$55.86SELL
EMA 50$53.96SELL
EMA 100$47.47BUY
EMA 200$38.43BUY
Current $ANAB · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Barclays2026-05-13
Maintains
OverweightOverweight
UBS2026-05-13
Maintains
BuyBuy
Piper Sandler2026-05-04
Maintains
OverweightOverweight
Leerink Partners2026-04-28
Maintains
OutperformOutperform
Barclays2026-04-22
Maintains
OverweightOverweight
UBS2026-04-21
Maintains
BuyBuy
Piper Sandler2026-03-31
Maintains
OverweightOverweight
HC Wainwright & Co.2026-03-30
Maintains
BuyBuy
UBS2026-03-17
Maintains
BuyBuy
Wedbush2026-03-12
Maintains
OutperformOutperform

Wall Street analysts have recently issued updated ratings on AnaptysBio, Inc. (ANAB) stock. Of the recent 112 rating actions, 9 were upgrades and 9 were downgrades. 22 analysts currently cover ANAB.

Analyst Recommendation Trends

Buy ratings633
Hold ratings101
Sell ratings00

ANAB analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 6 to 3 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$124M

↓ 58.2% YoY

Revenue Next Year

$172M

↑ 38.8% YoY

EPS This Year

$-2.04

EPS Next Year

$-2.34

↑ 15.1% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast ANAB EPS of $-2.04 for the current fiscal year, based on estimates from 4 analysts. The ANAB revenue forecast is $124M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The ANAB stock forecast is supported by two independent data sources: analyst consensus ratings from 22 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ANAB price target is $83.14 (+63.1% upside), with an analyst consensus of Buy.

The ANAB short-term stock prediction for tomorrow is $48.43 (-5.00%). The ANAB stock price prediction for 2027 estimates an average of $92. The ANAB stock prediction for 2030 projects a range of $193–$217.

AnaptysBio, Inc. trades on NASDAQ under the ticker ANAB. The ANAB stock outlook for 2027 is broadly positive, supported by a Buy consensus among 73% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

ANAB forecast · 8 questions

According to 22 Wall Street analysts, the average 12-month ANAB price target is $83.14, with a high forecast of $140.00 and a low of $50.00. The median price target is shown in the chart above when available. This implies +63.1% potential upside from the current price of $50.98.

ANAB price targetWhat is ANAB price targetANAB analyst price targetANAB 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.